Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer | Zendy

Martin Pölcher | Zendy; Meike Eckhardt | Zendy; Christoph Coch | Zendy; Matthias Wolfgarten | Zendy; Kirsten Kübler | Zendy; Gunther Hartmann | Zendy; Walther Kuhn | Zendy; Christian Rudlowski | Zendy

Open Access

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer

Author(s) -

Martin Pölcher,

Meike Eckhardt,

Christoph Coch,

Matthias Wolfgarten,

Kirsten Kübler,

Gunther Hartmann,

Walther Kuhn,

Christian Rudlowski

Publication year - 2010

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/s00280-010-1276-2

Subject(s) - sorafenib , medicine , carboplatin , oncology , tolerability , ovarian cancer , chemotherapy , endometrial cancer , clinical endpoint , paclitaxel , cancer , adverse effect , clinical trial , hepatocellular carcinoma , cisplatin

Sorafenib is a novel oral anticancer agent targeting signal transduction and angiogenic pathways through inhibitory effects against MAP kinases and vascular endothelial growth factor receptor-2. The objectives of this neoadjuvant phase II-trial in patients with advanced epithelial ovarian cancer were to assess the activity and tolerability of the combination therapy of carboplatin/paclitaxel with multi-target tyrosine kinase inhibitor sorafenib.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research